

AD\_\_\_\_\_

Award Number:

W81XWH-10-1-0164

TITLE: The Role of Rho GTPases in Breast Cancer  
Migration and Invasion

PRINCIPAL INVESTIGATOR:

Jeffery Smith

CONTRACTING ORGANIZATION:

Sloan Kettering Institute for Cancer Research

New York, NY 10065

REPORT DATE:

N\*ã↔ 2011

TYPE OF REPORT:

Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) FÂN*â↔→Á2011		2. REPORT TYPE Annual Summary		3. DATES COVERED (From - To) FIÁMar 2010 - FHÁMar 2011	
4. TITLE AND SUBTITLE The Role of Rho GTPases in Breast Cancer Migration and Invasion				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-10-1-0164	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S)  Jeffery Smith				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  Sloan-Kettering Institute for Cancer Research  New York, NY 10065				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT  Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Rho-family GTPases are the major regulators of the actin and microtubule cytoskeleton. Regulators of the GTPases include GEFs and GAPs, which control activation and deactivation, respectively, of this family of molecular switches. This study explores the role of the GEF Tiam2 in breast cancer cell proliferation and invasion, which was initially discovered using a siRNA screen in MDA-MB-231 breast cancer cells. Protein expression studies are performed using a panel of cell lines, revealing that Tiam2 expression is upregulated in Ras mutant cells. Additionally, Tiam2 depletion causes MDA-MB-231 cells to form fewer colonies in soft agar colony formation assays. Work continues on this project to determine how Tiam2 contributes to breast cancer proliferation and invasion using both cell culture and mouse models.					
15. SUBJECT TERMS Rho, GTPase, Tiam2					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT  None	18. NUMBER OF PAGES  6	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			19b. TELEPHONE NUMBER (include area code)

## Table of Contents

	<u>Page</u>
<b>Introduction.....</b>	<b>2</b>
<b>Body.....</b>	<b>3</b>
<b>Key Research Accomplishments.....</b>	<b>4</b>
<b>Reportable Outcomes.....</b>	<b>4</b>
<b>Conclusion.....</b>	<b>5</b>
<b>References.....</b>	<b>5</b>
<b>Appendices.....</b>	<b>5</b>

### Introduction

Rho family GTPases, members of the Ras superfamily, are best known for their regulation of the actin and microtubule cytoskeleton.[1] Misregulation of Rho signaling pathways can contribute to oncogenesis through effects on cell proliferation, adhesion, and migration.[2] There is evidence that mutations or alterations in expression levels of the Rho GTPase regulatory proteins, guanine nucleotide exchange factors (GEFs) and activating proteins (GAPs), contribute to inappropriate activation of Rho-mediated signal transduction pathways.[3, 4] Tiam2, a guanine nucleotide exchange factor (GEF), was identified in a siRNA screen for defects in breast cancer cell migration and invasion. Relatively little is known about the role of Tiam2 in regulating breast cancer migration, invasion, and proliferation as compared to the closely related protein Tiam1.[5-8] Both *in vitro* and *in vivo* approaches will be used to characterize how Tiam2 signals through Rho GTPases to control invasion and growth of MDA-MB-231 breast cancer cells. This study will allow for identification of possible drug targets in addition to expanding the understanding of Tiam2's physiological role in tumor progression.

## Body

A panel of cell lines was assembled that encompassed all many known breast cancer mutational statuses in addition to normal breast cell lines. Tiam1 and Tiam2 expression levels were compared [Figure 1]. Notably, expression of Tiam2 correlated with known Ras mutational status. Simple overexpression of mutant KRas V12 was insufficient to increase Tiam2 expression in HMEC and MCF-10a cells. Microarray expression data from the Oncomine database ([www.oncomine.org](http://www.oncomine.org)) was used to examine Tiam2 expression in human tumors, but no differences were observed. Comparison of mRNA (by qPCR) and protein levels in MDA-MB-231 cells and derivatives showed that Tiam2 probes on the microarray chips were unable to specifically detect changes in Tiam2 levels (data not shown).

To rescue the invasion defect caused by siRNA depletion of Tiam2, a full-length human Tiam2 cDNA was obtained. Silent mutations were introduced into this cDNA, causing it to become resistant to the siRNA targeted against the endogenous protein. This resistant Tiam2 cDNA was PCR cloned into pBabe retroviral plasmid to create stable, puromycin resistant MDA-MB-231 derived cell lines. These cell lines were treated with siRNA targeted to Tiam2 in an attempt to rescue the invasion phenotype. While it was possible to rescue the protein expression, the derivative cells were unable to invade through the matrigel. To determine if MDA-MB-231 cells harbor an activating mutation in Tiam2 (which may explain the lack of rescue), mRNA from these cells was isolated, reverse transcribed, and sequenced. Two known SNPs were found, but no other mutations that might alter protein function. This creates a significant problem for further domain analysis if the phenotype is not rescued by expression of a siRNA-resistant Tiam2 cDNA, and will impede work on both the invasion and proliferation *in vitro* studies.




Figure 1: Expression patterns of Tiam1 and Tiam2 in a panel of Breast Cancer Cell Lines.

A panel of shRNA lentivirus plasmids were obtained and used to create stable Tiam2-depleted MDA-MB-231-derived cell lines. These lines were then grown in soft agar to determine if Tiam2 expression affected anchorage-independent growth. Two of the plasmids were able to stably reduce Tiam2 protein levels and also reduced the number of colonies in soft agar [Figure 2]. Studies are currently underway to repeat the rescue experiments described in the previous paragraph to determine if colony growth can be rescued by




Figure 2: sh-10 and sh-13 deplete Tiam2 levels and most strongly inhibit the formation of colonies of MDA-MB-231 cells in soft agar.

retroviral expression of shRNA resistant Tiam2 cDNA. Work is still underway to determine what, if any, cell-cycle defects cause this growth inhibition both in soft-agar and in 2-D culture (including Annexin V, TUNEL staining, and BrdU incorporation assays).

The two hairpins used to successfully stably deplete Tiam2 in MDA-MB-231 colony formation assays were selected for use in a mouse tumorigenesis assay. Work has just begun in collaboration with the lab of Dr. Jacqueline Bromberg, to inject into NOD/SCID mice determine how Tiam2 affects tumor growth *in vivo*. Derivative cell lines will be isolated from these mice so that further *in vitro* characterization of signaling pathways affecting growth and invasion can be later explored more thoroughly. Specifically, the level of GTPase activation will be studied along with other possible effector molecular targets [9].

### Key Research Accomplishments

- Tiam2 expression is up-regulated in Ras mutant cancer cell lines.
- Tiam2 depletion inhibits the formation and growth of colonies in soft agar.
- Creation of MDA-MB-231 lines stably expressing siRNA-resistant Tiam2.
- Creation of MDA-MB-231 lines stably expressing shRNA depleting Tiam2 levels.

### Reportable Outcomes

- Poster Presentation: Jeffery R. Smith and Alan Hall; "The Role of Rho GTPases in Breast Cancer Invasion and Proliferation". 2011 Era of Hope Meeting in Orlando, FL.

## Conclusion

This study illustrates the importance of careful analysis of expression levels independent of microarray data. Increased expression of Tiam2 protein and mRNA in Ras-mutant breast cancer cell lines is unexpected and overlooked by previous work. Further studies should explore the link between these expression patterns as well as transcriptional regulation of protein expression during metastasis. Invasion studies, while slowed by the inability of Tiam2 overexpression to rescue invasion inhibition, still imply that Tiam2 could play a role in cell motility. Further work using animal models is currently underway to further elucidate the importance of Tiam2 in tumor formation, progression, and metastasis. This work will add insight into the molecular mechanisms by which cancer cells invade into surrounding tissue and eventually result in death.

## References

1. Etienne-Manneville, S. and A. Hall, *Rho GTPases in cell biology*. Nature, 2002. **420**(6916): p. 629-35.
2. Jaffe, A.B. and A. Hall, *Rho GTPases: biochemistry and biology*. Annual review of cell and developmental biology, 2005. **21**: p. 247-69.
3. Fritz, G., et al., *Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters*. British journal of cancer, 2002. **87**(6): p. 635-44.
4. Fritz, G., I. Just, and B. Kaina, *Rho GTPases are over-expressed in human tumors*. International journal of cancer. Journal international du cancer, 1999. **81**(5): p. 682-7.
5. Connolly, B.A., et al., *Tiam1-IRSp53 complex formation directs specificity of rac-mediated actin cytoskeleton regulation*. Molecular and cellular biology, 2005. **25**(11): p. 4602-14.
6. Chiu, C.Y., et al., *Cloning and characterization of T-cell lymphoma invasion and metastasis 2 (TIAM2), a novel guanine nucleotide exchange factor related to TIAM1*. Genomics, 1999. **61**(1): p. 66-73.
7. Mertens, A.E., R.C. Roovers, and J.G. Collard, *Regulation of Tiam1-Rac signalling*. FEBS letters, 2003. **546**(1): p. 11-6.
8. Nishimura, T., et al., *PAR-6-PAR-3 mediates Cdc42-induced Rac activation through the Rac GEFs STEF/Tiam1*. Nature cell biology, 2005. **7**(3): p. 270-7.
9. Garcia-Mata, R., et al., *Analysis of activated GAPs and GEFs in cell lysates*. Methods in enzymology, 2006. **406**: p. 425-37.

## Appendices

None.